ACFS (Antibody-Cytokine Fusion Protein)

---

Antibody-cytokine fusion proteins (ACFPs) constitute the foundation of KINE Biotech’s AI-enhanced immunotherapy development platform. These multifunctional biologics are engineered to integrate immune checkpoint inhibition with targeted immune stimulation, effectively addressing the intricacies of the tumor microenvironment (TME) by augmenting T-cell and/or NK cell activation while reducing systemic toxicity. KINE's leading ACFPs, such

as αPD1-IL2v (KN26) and αPDL1-IL2v (KN07), have exhibited enhanced efficacy compared to conventional immune checkpoint inhibitors in murine orthotopic models of lung and pancreatic cancer. In addition to immune checkpoints PD1 and PDL1, KINE's KN02 and KN09 specifically enhance anticancer immunity by targeting Her2-expressing tumors and the hypoxic tumor microenvironment, respectively.